RxDoctor Payments Data

Cindy Pontious

Psychiatric/Mental Health · West Des Moines, IANPI 1770925935

Payments from drug & device makers

$2,637in general payments, 2019–2025

Across 132 payments — averaging $19.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$338
  • Otsuka America Pharmaceutical, Inc.$298
  • Teva Pharmaceuticals USA, Inc.$221
  • Lundbeck LLC$166
  • Neurocrine Biosciences, Inc.$87
  • plus $292 from 8 others

What the payments were for

  • Food & beverage$2,58898%
  • Education$492%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,637 in reported general payments places this provider in the 75th percentile of 443 psychiatric/mental health providers in Iowa.

See all psychiatric/mental health providers in Iowa

Medicare billing

Part B allowed, 2024
$20,167
Medicare patients
67
Services billed
281

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine34$302,727
RexultiBrexpiprazole161$211,086
VraylarCariprazine Hcl99$141,526
Invega SustennaPaliperidone Palmitate22$59,212
Risperdal ConstaRisperidone Microspheres27$50,206
LybalviOlanzapine/Samidorphan Malate25$30,504
TrintellixVortioxetine Hydrobromide19$13,155
Aripiprazole238$9,691
Duloxetine Hcl385$8,464
Desvenlafaxine Succinate ErDesvenlafaxine Succinate202$8,104
Clozapine38$6,515
Lurasidone Hcl31$6,443
Bupropion XlBupropion Hcl366$6,403
Ziprasidone Hcl48$5,464
Quetiapine Fumarate350$5,256

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$221$302,72734 claims
Otsuka America Pharmaceutical, Inc.Rexulti$298$211,086161 claims
AbbVieVraylar$1,235$141,52699 claims
Johnson & JohnsonInvega Sustenna, Risperdal Consta$20$109,41849 claims
Alkermes, Inc.Lybalvi$52$30,50425 claims
Almatica Pharma LLCSertraline Hcl$48$65069 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 443 psychiatric/mental health providers in Iowa.

Other psychiatric/mental health in West Des Moines

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →